Paper Details

  1. Home
  2. Paper Details

Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy.

Author: ChengMeng Hsuan, ChongInn Wen, HuangHung Ling, HuangSing Han, HuangYu Wei, LeeChih Hsin, LeeJung Yu, LeeMeng Rui, LiuI Hsin, LoYu Shu, LuPo Liang, WangJann Yuan, YangJinn Moon

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study developed a 3-gene model for predicting systemic drug reaction (SDR) risk in patients receiving weekly rifapentine plus isoniazid for 12 doses (3HP) for latent tuberculosis infection (LTBI). The model achieved a sensitivity and specificity of 0.972 and 0.947, respectively, and worked well across different subgroups.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Systemic drug reaction (SDR) is a major safety concern with weekly rifapentine plus isoniazid for 12 doses (3HP) for latent tuberculosis infection (LTBI). Identifying SDR predictors and at-risk participants before treatment can improve cost-effectiveness of the LTBI program. METHODS: We...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477448/

データ提供：米国国立医学図書館（NLM）

Tuberculosis Preventive Therapy: A Personalized Approach

The fight against tuberculosis (TB), a persistent threat in the desert of human health, requires a multifaceted and personalized approach. This study, a guidepost through the complexities of TB preventive therapy, explores the potential of a whole-blood 3-gene signature to predict the risk of systemic drug reaction (SDR) to rifapentine-based therapy. The authors investigated the use of a gene-based signature to personalize treatment decisions, ultimately aiming to improve the safety and effectiveness of TB preventive therapy.

Gene-Based Signature: A Potential Predictor of SDR

The study's findings suggest that a whole-blood 3-gene signature, like a compass guiding us through the desert of TB preventive therapy, could effectively predict the risk of SDR to rifapentine-based therapy. The researchers identified a 3-gene model that achieved high sensitivity and specificity in predicting SDR, offering a potential tool for identifying individuals at higher risk of this serious adverse event. The study underscores the potential of personalized medicine to optimize treatment decisions and improve patient safety.

Personalized TB Prevention: A Key to Success

The study emphasizes the importance of a personalized approach to TB preventive therapy. The authors suggest that a gene-based signature could help identify individuals who are at higher risk of SDR, allowing for tailored treatment strategies to minimize the risk of adverse events. The study highlights the potential of personalized medicine to improve the safety and effectiveness of TB prevention programs, ultimately contributing to a healthier future for those at risk.

Dr.Camel's Conclusion

The desert of TB prevention is a challenging landscape, but with personalized approaches and innovative tools, we can navigate this terrain more effectively. This study, a beacon of hope in the pursuit of safer and more effective TB prevention, highlights the potential of a gene-based signature to personalize treatment decisions and improve patient outcomes.

Date :
  1. Date Completed 2022-09-19
  2. Date Revised 2022-12-11
Further Info :

Pubmed ID

34989801

DOI: Digital Object Identifier

PMC9477448

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.